Judging by the latest pricing data, Robert Hugin is still getting away with murder.

Last January, the Celgene (CELG) executive chairman sat alongside President Trump at a widely covered White House meeting to discuss pharmaceutical issues. The gathering was held shortly after Trump claimed drug makers are “getting away with murder” over their prices. And four months earlier, Allergan (AGN) chief executive Brent Saunders challenged other companies to hold their annual price hikes to single digits.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Our scribe has correctly reported Mr Schmidt’s number for the price increases. The math, ‘as written,’ is … interesting – 1.00 x 1.08 x 1.017 x 1.09 = 1.1978, at least on my simple calculator app. That 19.8 pct seems higher than the 14.1 pct that Mr Schmidt calls out … perhaps ‘average’ is what does it but the effective increase would be a hair below 20%. (Even simple addition yields 18.7% but …)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy